You started tirzepatide or retatrutide. The weight is dropping. Your appetite is under control for the first time in years. And then, around week 3 or 4, you hit a wall of fatigue that no amount of coffee can fix. Your energy tanks. Workouts feel impossible. Afternoon meetings become survival exercises.

This is not in your head. GLP-1 receptor agonists cause fatigue through at least three distinct metabolic mechanisms, and understanding them is the key to fixing the problem without abandoning the protocol that's actually working.

Mechanism 1: Aggressive caloric deficit and metabolic adaptation

GLP-1 peptides like [[Tirzepatide|10]] and [[Retatrutide|11]] suppress appetite through central and peripheral pathways. They slow gastric emptying, reduce ghrelin signaling, and alter hypothalamic hunger circuits. The result is that most users naturally consume 500-1000 fewer calories per day without trying.

That caloric gap triggers a cascade. Within 2-3 weeks of sustained deficit, the body starts downregulating resting metabolic rate. Thyroid hormone conversion (T4 to active T3) slows. Sympathetic nervous system output drops. Muscle protein synthesis decreases unless protein intake is deliberately high.

This is adaptive thermogenesis. Your metabolism is not broken. It is doing exactly what 200,000 years of evolution programmed it to do when food availability drops: conserve energy. The subjective experience of that conservation is fatigue, brain fog, and cold extremities.

The NAD+ angle. Every step of metabolic rate regulation depends on cellular energy currency. NAD+ (nicotinamide adenine dinucleotide) is the central coenzyme in the metabolic pathways that convert food into ATP. When caloric intake drops sharply, NAD+ demand increases relative to supply. Cells in high-energy tissues, especially brain, muscle, and liver, feel this deficit first. Supplementing with [[NAD+|14]] directly replenishes the coenzyme pool that caloric restriction depletes, supporting baseline energy production even when food intake is reduced.

Mechanism 2: Glucose volatility and insulin dynamics

GLP-1 agonists enhance glucose-dependent insulin secretion. This is why they are so effective for metabolic health. But the transition period, particularly during dose titration, can produce erratic blood glucose patterns.

Here is what happens: the peptide amplifies insulin response to meals. If you eat a carb-heavy meal, the enhanced insulin surge can overshoot, pulling blood glucose below your baseline 60-90 minutes after eating. This reactive hypoglycemia produces the classic energy crash: sudden fatigue, difficulty concentrating, irritability, sometimes shakiness.

Even without clinical hypoglycemia, the amplitude of glucose swings matters. A swing from 140 mg/dL to 80 mg/dL feels worse than sitting steady at 90 mg/dL, even though 80 is technically normal. Your brain, which consumes roughly 20% of daily glucose, is exquisitely sensitive to the rate of change.

How NAD+ stabilizes this. NAD+ is required for the function of sirtuins (SIRT1 and SIRT3), which regulate hepatic glucose output, insulin sensitivity, and mitochondrial fuel switching. When NAD+ levels are adequate, SIRT1 activates AMPK and improves the cell's ability to switch between glucose and fatty acid oxidation. This metabolic flexibility is exactly what blunts glucose swings. Instead of crashing when glucose drops, cells with healthy NAD+ levels smoothly transition to burning fat. The result is more stable energy throughout the day, even on a GLP-1 agonist.

Mechanism 3: Mitochondrial stress under dual metabolic load

This is the mechanism most people miss, and it may be the most important one.

Your mitochondria are simultaneously being asked to do two things during GLP-1 therapy: maintain normal ATP production for daily function AND ramp up fatty acid beta-oxidation because the body is mobilizing stored fat at an accelerated rate. Fat loss on [[Tirzepatide|10]] can reach 1-2 kg per week during the active phase. That fat has to go somewhere. It gets broken down into fatty acids, transported into mitochondria, and oxidized through the electron transport chain.

This dual demand generates increased reactive oxygen species (ROS). Some ROS is normal and even necessary for cellular signaling. But when mitochondrial throughput exceeds the cell's antioxidant capacity, oxidative stress accumulates. Mitochondrial efficiency drops. The organelles produce less ATP per unit of substrate. You feel this as deep, whole-body fatigue that does not improve with rest.

NAD+ directly addresses mitochondrial capacity. NAD+ is consumed by PARP enzymes during DNA repair (which increases under oxidative stress) and by CD38, an enzyme that rises with metabolic inflammation. Both of these pathways drain the NAD+ pool. Supplementing with [[NAD+|14]] restores the substrate that Complex I of the electron transport chain requires to shuttle electrons. More NAD+ means more efficient electron flow, more ATP per fatty acid molecule oxidized, and less ROS leakage. In a 2020 study published in Cell Metabolism, NAD+ precursor supplementation improved mitochondrial membrane potential and reduced markers of oxidative stress in human skeletal muscle.

The compounding problem: age-related NAD+ decline

If you are over 35, you are starting from a deficit. NAD+ levels decline approximately 50% between ages 20 and 50. This happens through increased CD38 expression (an NAD+-consuming enzyme that rises with chronic low-grade inflammation), reduced NAMPT activity (the rate-limiting enzyme in NAD+ salvage biosynthesis), and accumulated DNA damage that diverts NAD+ toward PARP-mediated repair.

So when a 40-year-old starts [[Retatrutide|11]] or [[Mazdutide|13]], their mitochondria are already operating with depleted NAD+ reserves. Adding the metabolic stress of rapid weight loss to an already-compromised NAD+ pool creates a predictable energy crisis. This is why fatigue on GLP-1 peptides tends to be worse in older users and in those with pre-existing metabolic dysfunction.

Practical protocol: combining GLP-1 agonists with NAD+

The fix is not to reduce your GLP-1 dose prematurely. If the peptide is working for weight loss, cutting the dose to manage fatigue means losing the therapeutic benefit. Instead, address the cellular energy deficit directly.

NAD+ injection protocol. Subcutaneous [[NAD+|14]] at 100-200mg, 2-3 times per week, is the most common research protocol for metabolic support. Injectable NAD+ bypasses the digestive system entirely, delivering the intact coenzyme to the bloodstream. This is a critical distinction from oral supplements like NMN or NR, which must survive gut metabolism, enter the liver, and undergo enzymatic conversion before becoming NAD+. Bioavailability of injectable NAD+ is substantially higher.

For users who prefer a simpler format, the [[NAD+ Pen|35]] offers pre-dosed convenience. No reconstitution, no insulin syringes, no measuring. Dial the dose, inject, done. This matters for adherence, especially when you are already managing a GLP-1 injection schedule.

Timing considerations. Administer NAD+ in the morning or early afternoon. NAD+ influences circadian clock gene expression through SIRT1, and evening dosing can interfere with sleep onset in some users. Separate NAD+ and GLP-1 injections by at least 4-6 hours; there is no known pharmacological interaction, but spacing injections reduces local tissue irritation.

Supporting interventions. NAD+ works best within a framework that minimizes the metabolic stressors causing the fatigue in the first place:

• Protein intake: minimum 1.6g/kg bodyweight daily. GLP-1-induced appetite suppression makes this hard, so prioritize protein at every meal. This protects lean mass and reduces the metabolic adaptation that drives fatigue.
• Electrolytes: reduced food intake means reduced electrolyte intake. Sodium, potassium, and magnesium depletion cause fatigue that mimics the metabolic fatigue described above. Supplement deliberately.
• Meal composition: shift toward protein and fat, moderate complex carbs, minimal simple sugars. This reduces the glucose swings that GLP-1 agonists can amplify.
• Resistance training: even 2-3 sessions per week signals the body to preserve muscle and maintain metabolic rate. This directly opposes adaptive thermogenesis.

What the research trajectory looks like

The NAD+ and GLP-1 combination is an area of active investigation. A 2023 review in Nature Aging highlighted sirtuins as key mediators of metabolic flexibility during caloric restriction, reinforcing the rationale for NAD+ repletion during weight loss. Separate research on NAD+ precursors in obese mouse models showed improved insulin sensitivity and reduced hepatic fat accumulation, effects that complement rather than compete with GLP-1 action.

The mechanistic logic is straightforward: GLP-1 agonists create the conditions for fat loss. NAD+ ensures the mitochondria can handle the workload that fat loss demands. Without adequate NAD+, you get the weight loss but pay for it with fatigue, brain fog, and exercise intolerance. With NAD+, the energy production machinery runs at capacity.

When to expect improvement

Most users report noticeable energy improvement within 5-7 days of starting NAD+ alongside their GLP-1 protocol. The initial response reflects direct coenzyme replenishment. The full benefit, including improved exercise tolerance and clearer cognition, typically stabilizes over 2-3 weeks as mitochondrial biogenesis catches up...